Background {#Sec1}
==========

Antiviral treatment for chronic hepatitis C (CHC) aims to prevent hepatitis C virus (HCV)-related morbidity and mortality, including complications of liver fibrosis or cirrhosis and the development of hepatocellular carcinoma (HCC). Treatment reduces the degree of necroinflammation of the liver and induces regression of hepatic fibrosis \[[@CR1]\]. Although direct-acting antivirals have recently emerged as a promising therapy, conventional interferon (IFN) or pegylated IFN (PegIFN) with or without ribavirin (RBV) has been used as the standard treatment for curing HCV.

A sustained virologic response (SVR) is the surrogate indicator for eradicating HCV and is considered to be "cure" \[[@CR2]\]. SVR24 or SVR12, which is the state of undetectable HCV RNA in a sensitive assay with a lower limit of detection \<50 IU/mL at week 24 or 12 after the end of treatment are accepted as an endpoint of treatment \[[@CR3]\].

The evolution of CHC is slow, and there is no specific symptom before progression to liver fibrosis. Due to delayed diagnosis of HCV-related chronic liver disease such as chronic hepatitis or liver fibrosis, it is difficult to start an anitviral treatment in the early stage of the disease. Previous study has demonstrated an achievement of SVR was associated with less risk for mortality (risk ratio 0.16) and development of HCC (risk ratio 0.37) \[[@CR4]\]. However, the majority of studies assessed short-term prognosis and the long-term clinical outcomes of antiviral therapy for patients with chronic hepatitis C are uncertain in terms of HCV-related morbidity and mortality, including disease progression to advanced hepatic fibrosis or cirrhosis, hepatic decompensation, HCC, and liver-specific death, especially according to the response to antiviral therapy. Moreover, viral replication of HCV is not known to be directly related to HCC development \[[@CR4]\].

The aim of this study was to assess the impact of antiviral treatment on the development of HCC and mortality in patients with CHC.

Methods {#Sec2}
=======

This systematic review and meta-analysis fully adhered to the principle of PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) checklist.

Literature searching strategy {#Sec3}
-----------------------------

PubMed, Embase, and the Cochrane Library were searched using common keywords associated with chronic hepatitis C, HCC, or SVR (from inception to April 2016) by 2 independent evaluators (C.S.B. and Y.J.Y.). Medical Subject Headings (MeSH) or Emtree keywords were selected for searching of electronic databases. The keywords included 'hepatitis C', 'HCV', 'hepatocellular carcinoma', 'HCC', 'sustained virologic response', 'SVR' and 'mortality'. These keywords were combined for a searching strategy using Boolean operators. The abstracts of all identified studies were reviewed to exclude irrelevant articles. Full-text reviews were performed to determine whether the inclusion criteria were satisfied by the remaining studies and the bibliographies of relevant articles were reviewed to identify additional studies. Disagreements between the evaluators were resolved by discussion or consultation with a third evaluator (I.H.S.). The detailed searching strategy is described in Table [1](#Tab1){ref-type="table"}.Table 1Clinical data of included studies1. PubMed1. Hepatitis C\[Mesh\] OR HCV\
2. HCC OR "hepatocellular carcinoma"\
3. SVR OR "sustained virologic response"\
4. Mortality\
(\#1 AND \#2) OR (\#1 AND \#3) OR (\#1 AND \#4) - \> removed duplicated articles2. Embase1. (hepatitis C or hcv).mp\
2. (hcc or hepatocellular carcinoma).mp\
3. (svr or sustained virologic reponse).mp\
4. mortality\
After accumulation of (1 and 2), (1 and 3), and (1 and 4), and then removed duplicated articles3. Cochrane library1. Hepatitis C OR HCV\
2. HCC OR "hepatocellular carcinoma"\
3. SVR OR "sustained virologic response"\
4. Mortality\
(\#1 AND \#2) OR (\#1 AND \#3) OR (\#1 AND \#4) - \> removed duplicated articles

Selection criteria {#Sec4}
------------------

We included randomized or non-randomized studies that met the following criteria: 1. Study designed to evaluate the efficacy of antiviral treatment on the development of HCC or mortality in CHC patients and a control group, or in CHC patients with SVR and the no SVR group; 2. Publications on human subjects; 3. Full-text publication; and 4. English language. Studies that met the all of the inclusion criteria were sought and selected. The exclusion criteria were as follows: 1. Incomplete data; 2. Review article; 3. Animal study; 4. Letter or case article; or 5. Abstract only publication. Studies meeting at least 1 of the exclusion criteria were excluded from this analysis.

Methodological quality {#Sec5}
----------------------

The methodological quality of the enrolled publications was assessed using the Risk of Bias table for randomized studies and the Newcastle-Ottawa Scale for non-randomized studies. The Risk of Bias was assessed as described in the Cochrane handbook by recording the method used to generate the randomization sequence, allocation concealment, determination of whether blinding was implemented for participants or staff, and evidence of selective reporting of the outcomes \[[@CR5]\]. Review Manager version 5.3.3 (Revman for Windows 7, the Nordic Cochrane Centre, Copenhagen, Denmark) was used to generate the Risk of Bias table. The Newcastle-Ottawa scale is categorized into three parameters: the selection of the study population, the comparability of the groups, and the ascertainment of the exposure or outcome. Each parameter consists of subcategorized questions: selection (*n* = 4), comparability (*n* = 1), and exposure or outcome (*n* = 3) \[[@CR6], [@CR7]\]. Stars that are awarded for each item serve as a quick visual assessment of the methodological quality of the studies. A study can be graded a maximum of 9 stars, which indicates the highest quality. Two of the evaluators (C.S.B. and Y.J.Y.) independently assessed the methodological quality of all studies, and any disagreements between the evaluators were resolved by discussion or consultation with a third evaluator (I.H.S.).

Primary and modifier-based analyses {#Sec6}
-----------------------------------

The following questions were primary topic of this meta-analyses: In patients with CHC, 1. Does the antiviral treatment reduce the development of HCC? 2. Does the antiviral treatment reduce all-cause or 3. liver-specific mortality? 4. Does the achievement of SVR reduce the development of HCC? 5. Does the achievement of SVR reduce all-cause or 6. liver-specific mortality?

The analysis was performed as 6 distinct meta-analyses to answer the 6 questions described above. Two evaluators (C.S.B. and Y.J.Y.) independently used the same data fill-up form to collect the primary summary outcome and modifiers in each study. The outcome was the relative rate of the development of HCC or mortality between antiviral treatment and the control groups, or the SVR and no SVR groups. These ratios were extracted and evaluated by odds ratios (ORs). Sensitivity analyses, including cumulative and one study removed analyses were performed to confirm the robustness of the main analysis results. These analyses were calculated in the order of publication year or effect size to find whether the time trend exists or which study is more or less influential in the pooled estimate. We also performed a meta-ANOVA and meta-regression to identify the reason of heterogeneity based on the multiple modifiers identified during systematic review. These reasons include study format (randomized/prospective cohort/retrospective cohort study), nationality, histology (degree of liver fibrosis), follow-up duration, Newcastle-Ottawa scale, age, and the regimen of the treatment (IFN, IFN with RBV, PegIFN with or without RBV). The follow-up duration of each study was categorized as long-term (≥5 years) or short-term (\<5 years).

Statistics {#Sec7}
----------

Comprehensive Meta-Analysis software (version 3, Biostat; Borenstein M, Hedges L, Higgins J and Rothstein H. Englewood, NJ, USA) was used for this meta-analysis. We calculated the ORs with 95% confidence intervals (CIs) using 2 × 2 tables from the original articles to evaluate the efficacy of antiviral treatment between the treatment and control groups, or the SVR and no SVR groups whenever possible. Heterogeneity was determined using the *I* ^*2*^ test developed by Higgins, which measures the percentage of total variation across studies \[[@CR8]\]. *I* ^*2*^ was calculated as follows: *I* ^*2*^ (%) = 100 × (Q-df)/Q, where Q is Cochrane's heterogeneity statistic and df signifies the degree of freedom. Negative values for *I* ^*2*^ were set to zero, and an *I* ^*2*^ value over 50% was considered to be of substantial heterogeneity (range: 0--100%) \[[@CR9]\]. Pooled-effect sizes with 95% CIs were calculated using a random effects model and the method of DerSimonian and Laird due to methodological heterogeneity \[[@CR10]\]. These results were confirmed by the *I* ^*2*^ test. Significance was set at *p* = 0.05. Publication bias was evaluated using Begg's funnel plot, Egger's test of the intercept, Begg and Mazumdar's rank correlation test, and Duval and Tweedie's trim and fill method \[[@CR11]--[@CR15]\].

Results {#Sec8}
=======

Identification of relevant studies {#Sec9}
----------------------------------

Figure [1](#Fig1){ref-type="fig"} presents a flow diagram of how relevant studies were identified. In total, 36,421 articles were identified by a search of 3 databases. In all, 7451 duplicate studies and an additional 28,481 studies were excluded during the initial screening through a review of the titles and abstracts. The full texts of the remaining 489 studies were then thoroughly reviewed. Among these studies, 431 articles were excluded from the final analysis. The reasons for study exclusion during the final review were as follows: review article (*n* = 12), incomplete data (*n* = 7), not meeting the inclusion criteria (*n* = 409), or abstract only study (*n* = 3). The remaining 58 studies \[4 randomized controlled studies (RCTs), 15 prospective cohort, and 40 retrospective cohort studies\] were included in the final analysis.Fig. 1Flow diagram for identification of relevant studies

Characteristics of included studies {#Sec10}
-----------------------------------

In each study topic, about 13--35 studies were enrolled. In terms of the study format, RCTs, prospective and retrospective cohort studies were mixed. The number of Western population-based studies and the number of Asian population-based studies were evenly distributed. The age of enrolled patients ranged from 37 to 64 years (median). The follow-up duration ranged from 32 months (mean) to 11.5 years (median). Most of the studies used IFN-based regimens with or without RBV in topic 1, 2 and 3. However, a PegIFN-based regimen and IFN-based regimens were evenly distributed in topic 4, 5, and 6. Underlying histology of liver was variable, but some studies exclusively assessing liver cirrhosis patients were included. The detailed characteristics of the included studies are described in Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}, and [6](#Tab6){ref-type="table"}.Table 2Clinical data summary of all included studiesTopicNumber of enrolled studies and populationStudy formatNationalityAgeFollow-up durationTreatment regimenHistologyTopic 125 studies (9691 treated vs. 6010 control)3 RCTs\
8 prospective cohort studies\
14 retrospective cohort studies15 Western population-based studies\
10 Asian population-based studies37 to 61 years (median)32 months to 10 years (mean)IFN-based regimens with or without RBV, except 4 studies with a PegIFN-based regimen10 studies exclusively assessing LC patients)Topic 217 studies (9868 treated vs. 4700 controls)1 RCT\
5 prospective cohort studies\
11 retrospective cohort studies8 Western population-based studies\
9 Asian population-based studies37 to 61 years (median)55 months to 11.5 years (median)IFN-based regimen with or without RBV, except 3 studies with a PegIFN-based regimen3 studies exclusively assessing LC patientsTopic 313 studies (8671 treated vs. 2831 controls)5 prospective cohort studies\
8 retrospective cohort studies5 Western population-based studies\
8 Asian population-based studies37 to 61 years (median)55 months to 11.5 years (median)IFN-based regimen with or without RBV, except 2 studies with a PegIFN-based regimen4 studies exclusively assessing LC patientsTopic 435 studies (14756 patients with SVR vs. 12741 patients with no SVR)1 RCT\
8 prospective cohort studies\
26 retrospective cohort studies17 Western population-based studies\
17 Asian population-based studies\
1 Saudi Arabia and Egypt population-based study37 to 64 years (median)2.1 (median) to 10 years (mean)20 studies with PegIFN-based regimen\
15 studies with IFN-based regimen9 studies exclusively assessing LC patientsTopic 522 studies (12440 patients with SVR vs. 18980 patients with no SVR)4 prospective cohort studies\
18 retrospective cohort studies12 Western population-based studies\
9 Asian population-based studies\
1 Saudi Arabia and Egypt population-based study41.8 to 64 years (mean)2.1 to 11.5 years (median)11 studies with PegIFN-based regimen\
11 studies with IFN-based regimen3 studies exclusively assessing LC patientsTopic 623 studies (5148 patients with SVR vs. 10356 patients with no SVR)7 prospective cohort studies\
16 retrospective cohort studies14 Western population-based studies\
9 Asian population-based studies41.8 to 64 (mean)2.1 to 11.5 years (median)12 studies with PegIFN-based regimen\
11 studies with IFN-based regimen6 studies exclusively assessing LC patients*RCT* randomized controlled study, *IFN* interferon, *PegIFN* pegylated interferon, *RBV* ribavirin, *LC* liver cirrhosis, *SVR* sustained virologic response Table 3Clinical data of included studies for the efficacy of antiviral treatment on the development of HCC in patients with CHCStudyNationalityAgeDuration of follow upStudy formatGenotypeNOSTreatmentHCC/Total treatmentHCC/ControlHistologyMazella G et al. (1996) \[[@CR23]\]ItalyTx: 53, control: 54 (mean)mean 32 monthsPunknown7IFN-α or lymphoblastoid5/1939/92Child A LCBruno S et al.(1997) \[[@CR24]\]ItalyTx 56, control: 59 (mean)median 68 monthsP62% type 1b7IFN-α6/8316/80LC (mainly Child A)Fattovich G et al. (1997) \[[@CR25]\]ItalyTx: 53, control: 57 (mean)mean 60 monthsRunknown8IFN-α7/19316/136LCSerfaty L et al. (1998) \[[@CR26]\]FranceTx: 55, control: 56 (mean)median 40 monthsP48% 1b7IFN-α2/599/44Knodell 10 (mean)Benvegnù L et al.(1998) \[[@CR27]\]ItalyTx: 56.7, control: 59.5 (mean)mean 71.5 monthsPunknown8IFN4/7520/77Child A LCInternational Interferon-α Hepatocellular Carcinoma Study Group (1998) \[[@CR28]\]Italy and Argentina54 (median)36 monthsRunknown7IFN-α or lymphoblastoid21/23248/259unknownImai Y et al.(1998) \[[@CR29]\]JapanunknownTx: 47.6, control: 46.8 (median)Runknown7IFN-α28/41919/144F3,4: 37% in Tx, 53% in controlYoshida H et al. (1999) \[[@CR30]\]JapanTx: 49.5, control: 53.6 (mean)median 4.3 yearsR70.3% type 17IFN-α or IFN-β or combination89/240059/490F3,4: 33.1% in Tx, 33.8% in controlOkanoue T et al. (1999) \[[@CR31]\]Japan42.6--57.6 (mean)mean 39.5--67.1 monthsRunknown7IFN-α or lymphoblastoid52/114822/55F3,4: 34% in Tx, F4: 100% in controlValla DC et al. (1999) \[[@CR32]\]FranceTx: 57, control: 56 (mean)mean 160 weeksRCTunknownIFN-α5/479/52compensated LCIkeda K et al. (2001) \[[@CR33]\]Japan57 (median)median 7.6 yearsRunknown7IFN-α or IFN-β32/113271/581LCGramenzi A et al. (2001) \[[@CR34]\]ItalyTx: 57.9, control: 58.1 (mean)median 55--58 monthsPunknown7IFN-α6/7219/72LC (mainly Child A)Nishiguchi S et al. (2001) \[[@CR35]\]JapanTx: 54.7, control: 57.3 (mean)mean 8.2 yearsRCT75.6% type 2IFN-α12/4533/45unknownTestino G et al. (2002) \[[@CR16]\]ItalyTx: 55.3, control: 56.8 (mean)mean 95.4 monthsR55% type 1b, 45% type 28IFN-α12/5124/71Child A LCCoverdale SA et al. (2004) \[[@CR36]\]AustraliaTx: 37, control: 38 (median)median 9 yearsP39.6% type 17IFN-α26/3847/71Scheuer fibrosis score 2Azzaroli F et al. (2004) \[[@CR37]\]Italy55.1 (mean)5 yearsRCT64.4% type 1bIFN-α with RBV2/719/30LCShiratori Y et al. (2005) \[[@CR38]\]JapanTx: 57, control: 61 (median)median 6.8 yearsP71.9% type 1b8IFN-α or lymphoblastoid84/27135/74unknownYu ML et al. (2006) \[[@CR39]\]TaiwanTx: 46.9, control: 43.6 (mean)mean 5.18--5.15 yearsR46.2% type 18IFN-α with or without RBV51/105754/562LC 15.6% in Tx, 12.1% in controlSinn DH et al. (2008) \[[@CR40]\]Korea48.4--58.2 (mean)median 55.2 monthsR48.6% type 27IFN/PegIFN with or without RBV14/490122/647F3,4: 49% in Tx, F4: 33% in controlDi Martino V et al. (2011) \[[@CR41]\]Franceunknownmedian 59 monthsR57.9% type 17IFN with or without RBV, or PegIFN with RBV9/1845/18455.5% F2 or greaterTateyama M et al. (2011) \[[@CR42]\]Japan57 (median)mean 8.2 yearsR72.1% type 1b8IFN/PegIFN with or without RBV110/37363/334F3,4: 34.1%Maruoka D et al. (2012) \[[@CR43]\]Japan50.4--54 (mean)mean 9.9 yearsR73.6% type 18IFN-α/IFN-β with or without RBV85/57735/144F3,4: 24.3% in Tx, F4: 43.1% in controlCozen ML et al. (2013) \[[@CR44]\]US50.98 (mean)mean 10 yearsR68.7% type 18IFN-α with or without RBV11/1599/199F3,4: 19% (30.2% in Tx, 10.1% in control)Aleman S et al. (2013) \[[@CR45]\]Sweden51 (mean)mean 5.3 yearsR50% type 18PegIFN with RBV32/30314/48LCCozen ML et al. (2016) \[[@CR46]\]US51.4 (mean)mean 8.5 yearsP71.6% type 1 or 48IFN-α with RBV43/69284/1519LC 15.8% in Tx, 5.3% in control*HCC* hepatocellular carcinoma, *CHC* chronic hepatitis C, *NOS* Newcastle-Ottawa scale, *Tx* treatment group, *R* retrospective cohort study, *P* prospective cohort study, *RCT* randomized controlled study, *IFN* interferon, *PegIFN* pegylated interferon, *RBV* ribavirin, *LC* liver cirrhosis Table 4Clinical data of included studies for the efficacy of antiviral treatment on all-cause and liver-specific mortality in patients with CHCStudyNationalityAgeDuration of follow upStudy formatGenotypeNOSTreatmentDeath/Total treatmentDeath/ControlHistologyBenvegnù L et al. (1998) \[[@CR27]\]ItalyTx: 56.7, control: 59.5 (mean)mean 71.5 monthsPunknown8IFN^a^3/75^a^15/77Child A LCIkeda K et al. (2001) \[[@CR33]\]Japan57 (median)median 7.6 yearsRunknown7IFN-α or IFN-β20/113 ^a^12/113266/581 ^a^124/581LCGramenzi A et al. (2001) \[[@CR34]\]ItalyTx: 57.9, control: 58.1 (mean)median 55--58 monthsPunknown7IFN-α^a^7/729/72 ^a^8/72LC (mainly Child A)Nishiguchi S et al. (2001) \[[@CR35]\]JapanTx: 54.7, control: 57.3 (mean)mean 8.2 yearsRCT75.6% type 2IFN-α5/4526/45unknownTestino G et al. (2002) \[[@CR16]\]ItalyTx: 55.3, control: 56.8 (mean)mean 95.4 monthsR55% type 1b, 45% type 28IFN-α1/519/71Child A LCYosida H et al. (2002) \[[@CR47]\]JapanTx: 49.5, control: 54.6 (mean)mean 5.4 yearsRunknown8IFN-α or IFN-β56/2430 ^a^35/243030/459 ^a^23/459F3,4: 32.2% in Tx, 31.6% in control, 26.3% in SVR, 35.2% in no SVRImazeki F et al. (2003) \[[@CR48]\]JapanTx: 49.2, control: 53.1 (mean)mean 8.2 yearsR73.9% type 18IFN-α or IFN-β33/355 ^a^19/35515/104 ^a^12/104F3,4: 26.7% in Tx, 29.8% in control,Coverdale SA et al. (2004) \[[@CR36]\]AustraliaTx: 37, control: 38 (median)median 9 yearsP39.6% type 17IFN-α^a^36/384^a^12/71Scheuer fibrosis score 2Kasahara A et al. (2004) \[[@CR17]\]JapanTx: 53, control: 54 (median)mean 6 yearsRunknown8IFN101/2698 ^a^69/269852/256 ^a^42/256F3,4: 38.7% in Tx, 48% in control, 28.6% in SVR, 43% in no SVRShiratori Y et al. (2005) \[[@CR38]\]JapanTx: 57, control: 61 (median)median 6.8 yearsP71.9% type 1b8IFN-α or lymphoblastoid45/271 ^a^32/27124/74 ^a^19/74unknownYu ML et al. (2006) \[[@CR39]\]TaiwanTx: 46.9, control: 43.6 (mean)mean 5.18--5.15 yearsR46.2% type 18IFN-α with or without RBV16/1057 ^a^14/105712/562 ^a^10/562LC 15.6% in Tx, 12.1% in controlDi Martino V et al. (2011) \[[@CR41]\]Franceunknownmedian 59 monthsR57.9% type 17IFN with or without RBV, or PegIFN with RBV9/184 ^a^5/18420/194 ^a^4/18455.5% F2 or greaterYamasaki K et al. (2012) \[[@CR49]\]Japan60.9 (mean)median 11.5 yearsP59.9% type 1b7IFN-α or β or lymphoblastoid with or without RBV25/152 ^a^6/15290/199 ^a^32/199unknownMaruoka D et al. (2012) \[[@CR43]\]Japan50.4--54 (mean)mean 9.9 yearsR73.6% type 18IFN-α/IFN-β with or without RBV84/577 ^a^52/57737/144 ^a^30/144F3,4: 24.3% in Tx, F4: 43.1% in controlCozen ML et al. (2013) \[[@CR44]\]US50.98 (mean)mean 10 yearsR68.7% type 18IFN-α with or without RBV31/15947/199F3,4: 19% (30.2% in Tx, 10.1% in control)Aleman S et al. (2013) \[[@CR45]\]Sweden51 (mean)mean 5.3 yearsR50% type 18PegIFN with RBV59/303 ^a^39/30318/48 ^a^16/48LCKutala BK et al. (2015) \[[@CR50]\]France50 (median)median 5.5 yearsR55.7% type 18IFN/PegIFN with or without RBV30/32519/102F3,4: 100%Cozen ML et al. (2016) \[[@CR46]\]US51.4 (mean)mean 8.5 yearsP71.6% type 1 or 48IFN-α with RBV112/692488/1519LC 15.8% in Tx, 5.3% in control^a^: Liver-specific death, *CHC* chronic hepatitis C, *NOS* Newcastle-Ottawa scale, *Tx* treatment group, *R* retrospective cohort study, *P* prospective cohort study, *RCT* randomized controlled study, *IFN* interferon, *PegIFN* pegylated interferon, *RBV* ribavirin, *LC* liver cirrhosis, *SVR* sustained virologic response Table 5Clinical data of included studies for the efficacy of SVR on the development of HCC in patients with CHCStudyNationalityAgeDuration of follow upStudy formatGenotypeNOSTreatmentHCC/Total SVRHCC/No SVRHistologyNishiguchi S et al. (1995) \[[@CR51]\]JapanTx: 54.7, control: 57.3 (mean)2--7 yearsRCT75.6% type 2IFN-α0/72/38HAI 11.7 in Tx, 11.8 in control (mean)Tanaka K et al. (1998) \[[@CR52]\]JapanSVR: 47.7, no SVR: 51 (mean)about 40 monthsPunknown7lymphoblastoid IFN0/810/47LCYoshida H et al. (1999) \[[@CR30]\]JapanTx: 49.5, control: 53.6 (mean)median 4.3 yearsR70.3% type 17IFN-α or IFN-β or combination10/78979/1611F3,4: 33.1% in Tx, 33.8% in controlTestino G et al. (2002) \[[@CR16]\]ItalyTx: 55.3, control: 56.8 (mean)mean 95.4 monthsR55% type 1b, 45% type 28IFN-α3/1112/40Child A LCOkanoue T et al. (2002) \[[@CR53]\]JapanTx: 50.4, control: 58.1 (mean)Mean 5.6 yearsRunknown7IFN-α or lymphoblastoid4/426110/994F3,4: 20.9% in SVR, 34.4% in controlCoverdale SA et al. (2004) \[[@CR36]\]AustraliaTx: 37, control: 38 (median)median 9 yearsP39.6% type 17IFN-α1/5025/334Scheuer fibrosis score 2Shiratori Y et al. (2005) \[[@CR38]\]JapanTx: 57, control: 61 (median)median 6.8 yearsP71.9% type 1b8IFN-α or lymphoblastoid11/6473/207unknownYu ML et al. (2006) \[[@CR39]\]TaiwanTx: 46.9, control: 43.6 (mean)mean 5.18--5.15 yearsR46.2% type 18IFN-α with or without RBV12/71539/342LC 15.6% in Tx, 12.1% in controlPradat P et al. (2007) \[[@CR54]\]Europe45--47 (mean)5--7 yearsP49.2% type 16IFN/PegIFN with or without RBV0/9117/266unknownBraks RE et al. (2007) \[[@CR55]\]France54.1 (mean)mean 7.7 yearsR61.1% type 18IFN-α with or without RBV, or PegIFN with RBV1/3724/76Child A LCBruno S et al. (2007) \[[@CR56]\]Italy54.7 (mean)Mean 96.1 monthsR71.8% type 18IFN-α7/124122/759Child A LCHasegawa E et al. (2007) \[[@CR57]\]Japan56 (median)median 4.6 yearsR65% 2a7IFN-α,β/lymphoblastoid with or without RBV3/4816/57LCVeldt BJ et al. (2007) \[[@CR58]\]Europe and Canada48 (median)median 2.1 yearsR59% type 18IFN/PegIFN with or without RBV3/14232/337Ishak 4--6Floreani A et al. (2008) \[[@CR59]\]Italy44.5--55.7 (mean)mean 23.4--25.2 monthsR41.3% type 17PegIFN with RBV0/405/38unknownSinn DH et al. (2008) \[[@CR40]\]Korea48.4--58.2 (mean)median 55.2 monthsR48.6% type 27IFN/PegIFN with or without RBV4/29610/194F3,4: 49% in Tx, F4: 33% in controlKurokawa M et al. (2009) \[[@CR60]\]Japan55.8 (mean)median 36.5 monthsR72.9% type 17IFN-α with RBV4/13921/264F3,4: 31.3%Asahina Y et al. (2010) \[[@CR61]\]Japan55.4 (mean)mean 7.5 yearsR69.6% type 1b8IFN-α,β with or without RBV, or PegIFN with RBV22/686149/1356F3,4: 25.2%Kawamura Y et al. (2010) \[[@CR62]\]Japan50 (median)median 6.7 yearsRunknown8IFN-α,β with or without RBV12/108161/977F1,2: 93.1%Cardoso AC et al. (2010) \[[@CR63]\]France55 (mean)median 3.5 yearsR60% type 17IFN/PegIFN with or without RBV6/10340/204F3,4: 100%Morgan TR et al. (2010) \[[@CR64]\]US48.6--49.6 (mean)median 79--96 monthsP87.2% type 18PegIFN with or without RBV2/14033/386F3,4: 100%Di Martino V et al. (2011) \[[@CR41]\]Franceunknownmedian 59 monthsR57.9% type 17IFN with or without RBV, or PegIFN with RBV1/598/12555.5% F2 or greaterVelosa J et al. (2011) \[[@CR65]\]Portugal51.7 (mean)mean 6.4 yearsR61% type 17IFN/PegIFN with or without RBV1/3920/91compensated LCIacobellis A et al. (2011) \[[@CR66]\]Italy59--62 (mean)mean 51 monthsP57.3% type 17PegIFN with RBV5/2411/51decompensated LCHung CH et al. (2011) \[[@CR67]\]Taiwan53 (median)median 4.3 yearsR49% type 17IFN/PegIFN with or without RBV33/102754/443unknownTakahashi H et al. (2011) \[[@CR68]\]Japan55.4 (mean)Mean 52 monthsR74.9% type 1b7IFN-α,β/PegIFN with RBV1/8912/114F3,4: 23.2%Backus LI et al. (2011) \[[@CR69]\]US51--53 (mean)median 3.8 yearsR72.1% type 16PegIFN with RBV223/7434283/144013% LCTateyama M et al. (2011) \[[@CR42]\]Japan57 (median)mean 8.2 yearsR72.1% type 1b8IFN/PegIFN with or without RBV3/13944/234F3,4: 34.1%Osaki Y et al. (2012) \[[@CR70]\]Japan59 (median)median 4.1 yearsR59.9% type 17IFN/PegIFN with RBV1/18522/197unknownvan der Meer AJ et al. (2012) \[[@CR71]\]Europe and Canada48 (mean)median 8.4 yearsR68% type 18IFN/PegIFN with or without RBV7/12576/405Ishak 4--6Maruoka D et al. (2012) \[[@CR43]\]Japan50.4--54 (mean)mean 9.9 yearsR73.6% type 18IFN-α/IFN-β with or without RBV5/22180/356F3,4: 24.3% in Tx, F4: 43.1% in controlCozen ML et al. (2013) \[[@CR44]\]US50.98 (mean)mean 10 yearsR68.7% type 18IFN-α with or without RBV2/699/90F3,4: 19% (30.2% in Tx, 10.1% in control)Alfaleh FZ et al. (2013) \[[@CR72]\]Saudi Arabia, Egypt48 (mean)mean 63.8 monthsP30.6% type 48PegIFN with or without RBV0/624/95F3,4: 24.6% (27.1% in SVR, 31.1% in no SVR)Aleman S et al. (2013) \[[@CR45]\]Sweden51 (mean)mean 5.3 yearsR50% type 18PegIFN with RBV6/11026/193LCDi Marco V et al. (2016) \[[@CR73]\]Italy58 (mean)median 7.6 yearsP83.4% type 18PegIFN with RBV7/10892/336compensated LCIkezaki H et al. (2016) \[[@CR74]\]Japan60--64 (median)median 2.8 yearsR52.7% in type 17IFN- β with RBV2/687/44F3,4: 30.9% in SVR, 72.7% in no SVR*SVR* sustained virologic response, *HCC* hepatocellular carcinoma, *CHC* chronic hepatitis C, *NOS* Newcastle-Ottawa scale, *Tx* treatment group, *R* retrospective cohort study, *P* prospective cohort study, *RCT* randomized controlled study, *IFN* interferon, *PegIFN* pegylated interferon, *RBV* ribavirin, *LC* liver cirrhosis Table 6Clinical data of included studies for the efficacy of SVR on all-cause and liver-specific mortality in patients with CHCStudyNationalityAgeDuration of follow upStudy formatGenotypeNOSTreatmentDeath/Total SVRDeath/No SVRHistologyYosida H et al. (2002) \[[@CR47]\]JapanTx: 49.5, control: 54.6 (mean)mean 5.4 yearsRunknown8IFN-α or IFN-β^a^7/817^a^49/1613F3,4: 32.2% in Tx, 31.6% in control, 26.3% in SVR, 35.2% in no SVROkanoue T et al. (2002) \[[@CR53]\]JapanTx: 50.4, control: 58.1 (mean)Mean 5.6 yearsRunknown7IFN-α or lymphoblastoid2/426 ^a^0/42647/994 ^a^34/994F3,4: 20.9% in SVR, 34.4% in controlImazeki F et al. (2003) \[[@CR48]\]JapanTx: 49.2, control: 53.1 (mean)mean 8.2 yearsR73.9% type 18IFN-α or IFN-β4/116 ^a^1/11629/239 ^a^18/239F3,4: 26.7% in Tx, 29.8% in controlCoverdale SA et al. (2004) \[[@CR36]\]AustraliaTx: 37, control: 38 (median)median 9 yearsP39.6% type 17IFN-α^a^1/50^a^35/334Scheuer fibrosis score 2Kasahara A et al. (2004) \[[@CR17]\]JapanTx: 53, control: 54 (median)mean 6 yearsRunknown8IFN7/738 ^a^1/73894/1930 ^a^68/1930F3,4: 38.7% in Tx, 48% in control, 28.6% in SVR, 43% in no SVRShiratori Y et al. (2005) \[[@CR38]\]JapanTx: 57, control: 61 (median)median 6.8 yearsP71.9% type 1b8IFN-α or lymphoblastoid1/64 ^a^0/6444/207 ^a^32/207unknownYu ML et al. (2006) \[[@CR39]\]TaiwanTx: 46.9, control: 43.6 (mean)mean 5.18--5.15 yearsR46.2% type 18IFN-α with or without RBV4/715 ^a^3/71512/342 ^a^11/342LC 15.6% in Tx, 12.1% in controlArase Y et al. (2007) \[[@CR75]\]JapanSVR: 63, no SVR: 64 (mean)mean 7.4 yearsR60.4% type 1b8IFN-α/β with or without RBV9/140 ^a^2/14044/360 ^a^32/360F3,4: 14.5 in SVR, 27.5 in no SVRBruno S et al. (2007) \[[@CR56]\]Italy54.7 (mean)Mean 96.1 monthsR71.8% type 18IFN-α6/124 ^a^2/120114/759 ^a^83/728Child A LCVeldt BJ et al. (2007) \[[@CR58]\]Europe and Canada48 (median)median 2.1 yearsR59% type 18IFN/PegIFN with or without RBV2/142 ^a^1/14224/337 ^a^19/337Ishak 4--6Cardoso AC et al. (2010) \[[@CR63]\]France55 (mean)median 3.5 yearsR60% type 17IFN/PegIFN with or without RBV^a^3/103^a^18/204F3,4: 100%Morgan TR et al. (2010) \[[@CR64]\]US48.6--49.6 (mean)median 79--96 monthsP87.2% type 18PegIFN with or without RBV^a^1/140^a^23/386F3,4: 100%Innes HA et al. (2011) \[[@CR76]\]UK41.8 (mean)mean 5.3 yearsR35.6% type 18IFN/PegIFN with or without RBV13/560 ^a^5/56075/655 ^a^50/65585.8% no LCDi Martino V et al. (2011) \[[@CR41]\]Franceunknownmedian 59 monthsR57.9% type 17IFN with or without RBV, or PegIFN with RBV0/59 ^a^0/599/125 ^a^5/12555.5% F2 or greaterVelosa J et al. (2011) \[[@CR65]\]Portugal51.7 (mean)mean 6.4 yearsR61% type 17IFN/PegIFN with or without RBV^a^0/39^a^15/91compensated LCIacobellis A et al. (2011) \[[@CR66]\]Italy59--62 (mean)mean 51 monthsP57.3% type 17PegIFN with RBV^a^2/24^a^23/51decompensated LCBackus LI et al. (2011) \[[@CR69]\]US51--53 (mean)median 3.8 yearsR72.1% type 16PegIFN with RBV525/74341440/943013% LCYamasaki K et al. (2012) \[[@CR49]\]Japan60.9 (mean)median 11.5 yearsP59.9% type 1b7IFN-α or β or lymphoblastoid with or without RBV9/72 ^a^1/7216/80 ^a^5/80unknownvan der Meer AJ et al. (2012) \[[@CR71]\]Europe and Canada48 (mean)median 8.4 yearsR68% type 18IFN/PegIFN with or without RBV13/125 ^a^3/125100/405 ^a^103/405Ishak 4--6Maruoka D et al. (2012) \[[@CR43]\]Japan50.4--54 (mean)mean 9.9 yearsR73.6% type 18IFN-α/IFN-β with or without RBV10/221 ^a^2/22174/356 ^a^50/356F3,4: 24.3% in Tx, F4: 43.1% in controlCozen ML et al. (2013) \[[@CR44]\]US50.98 (mean)mean 10 yearsR68.7% type 18IFN-α with or without RBV6/6925/90F3,4: 19% (30.2% in Tx, 10.1% in control)Alfaleh FZ et al. (2013) \[[@CR72]\]Saudi Arabia, Egypt48 (mean)mean 63.8 monthsP30.6% type 48PegIFN with or without RBV0/62 ^a^0/624/95 ^a^8/95F3,4: 24.6% (27.1% in SVR, 31.1% in no SVR)Aleman S et al. (2013) \[[@CR45]\]Sweden51 (mean)mean 5.3 yearsR50% type 18PegIFN with RBV11/110 ^a^4/11048/193 ^a^35/193LCSingal AG et al. (2013) \[[@CR77]\]US48 (median)median 36--72 monthsR68.6% type 17PegIFN with RBV2/8341/15917.3% LCDieperink E et al. (2014) \[[@CR78]\]US51.4 (mean)median 7.5 yearsR70% type 18IFN/PegIFN with or without RBV19/222 ^a^6/22281/314 ^a^56/314F3,4: 54.5% (41.3% in SVR, 64.7% in no SVR)Kutala BK et al. (2015) \[[@CR50]\]France50 (median)median 5.5 yearsR55.7% type 18IFN/PegIFN with or without RBV3/10427/221F3,4: 100%Di Marco V et al. (2016) \[[@CR73]\]Italy58 (mean)median 7.6 yearsP83.4% type 18PegIFN with RBV^a^8/108^a^98/336compensated LC^a^: Liver-specific death, *SVR* sustained virologic response, *CHC* chronic hepatitis C, *NOS* Newcastle-Ottawa scale, *Tx* treatment group, *R* retrospective cohort study, *P* prospective cohort study, *RCT* randomized controlled study, *IFN* interferon, *PegIFN* pegylated interferon, *RBV* ribavirin, *LC* liver cirrhosis

Methodological quality {#Sec11}
----------------------

The methodological quality of cohort study is described in the Table [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}. This feature was evaluated as modifiers in each analysis. The methodological quality of RCT is described in Additional file [1](#MOESM1){ref-type="media"}: Appendix 1. Given the similar methodological quality among RCTs, sensitivity analysis or subgroup analyses based on the methodological quality in RCTs were not performed.

Efficacy of antiviral treatment on the development of HCC in chronic hepatitis C patients {#Sec12}
-----------------------------------------------------------------------------------------

The overall efficacy of antiviral treatment on the development of HCC exhibited an OR of 0.392 (95% CI: 0.275--0.557, *p* \<0.001) in a random effect model analysis (Fig. [2](#Fig2){ref-type="fig"}). The funnel plot showed asymmetry on the right lower quadrant area (Additional file [1](#MOESM1){ref-type="media"}: Appendix Figure S2). However, the Egger's test revealed an intercept of −2.131 (95% CI: −4.81--0.54, t-value: 1.64, df: 23, *p* = 0.11 (2-tailed)). The rank correlation test also showed a Kendall's tau of −0.19 with a continuity correction (*p* = 0.17). The trim and fill method indicated that no study was trimmed. Overall, there was no evidence of publication bias.Fig. 2Efficacy of antiviral treatment on the development of HCC in patients with CHC. The size of each square is proportional to the study's weight. Diamond is the summary estimate from the pooled studies (random effect model). HCC, hepatocellular carcinoma; CHC, chronic hepatitis C

A cumulative meta-analysis of enrolled studies based on publication year showed no specific time trend (Additional file [1](#MOESM1){ref-type="media"}: Appendix 3). A cumulative meta-analysis based on effect size showed no small study bias (Additional file [1](#MOESM1){ref-type="media"}: Appendix 4). One study removed meta-analysis revealed a stable feature (Additional file [1](#MOESM1){ref-type="media"}: Appendix 5). Overall, the sensitivity meta-analyses revealed robust results.

Methodological quality of Newcastle-Ottawa scale potentially explained heterogeneity in meta-ANOVA tests (*p* = 0.027) (Additional file [1](#MOESM1){ref-type="media"}: Appendix 6). A meta-regression revealed a Newcastle-Ottawa scale score of 8 for the reason of heterogeneity (*p* = 0.027) (Additional file [2](#MOESM2){ref-type="media"}: Table S1). After excluding 10 studies (Newcastle-Ottawa scale 8), no covariates explained heterogeneity in meta-regression tests. Therefore, methodological quality was the reason of heterogeneity in this analysis.

Efficacy of antiviral treatment on All-cause mortality in patients with chronic hepatitis C {#Sec13}
-------------------------------------------------------------------------------------------

The overall efficacy of antiviral treatment on all-cause mortality revealed an OR of 0.380 (95% CI: 0.295--0.489, *p* \<0.001) in a random effect model analysis (Fig. [3](#Fig3){ref-type="fig"}). The funnel plot showed asymmetry on the right lower quadrant area (Additional file [1](#MOESM1){ref-type="media"}: Appendix 7). However, the Egger's test revealed an intercept of 0.266 (95% CI: −2.010--2.542, t-value: 0.25, df: 15, *p* = 0.81 (2-tailed)). The rank correlation test also showed a Kendall's tau of 0.04 with a continuity correction (*p* = 0.84). The trim and fill method indicated that 1 study was trimmed. After excluding the study by Testino et al. \[[@CR16]\] located on the left lower quadrant in funnel plot, the OR was 0.385 (95% CI: 0.298--0.496, *p* \<0.001). Overall, the impact of bias was minimal.Fig. 3Efficacy of antiviral treatment on all-cause mortality in patients with CHC. The size of each square is proportional to the study's weight. Diamond is the summary estimate from the pooled studies (random effect model). CHC, chronic hepatitis C

A cumulative meta-analysis of enrolled studies based on publication year showed no specific time trend (Additional file [1](#MOESM1){ref-type="media"}: Appendix 8). A cumulative meta-analysis based on effect size showed no small study bias (Additional file [1](#MOESM1){ref-type="media"}: Appendix 9). One study removed meta-analysis revealed a stable feature (Additional file [1](#MOESM1){ref-type="media"}: Appendix 10). Overall, the sensitivity meta-analyses revealed robust results.

Meta-ANOVA or meta-regression showed no specific modifier for the reason of heterogeneity (Additional file [1](#MOESM1){ref-type="media"}: Appendix 11) (Additional file [2](#MOESM2){ref-type="media"}: Table S2). Overall, no covariates were found to be explaining heterogeneity in this meta-analysis.

Efficacy of antiviral treatment on liver-specific mortality in chronic hepatitis C patients {#Sec14}
-------------------------------------------------------------------------------------------

The overall efficacy of antiviral treatment on liver-specific mortality exhibited an OR of 0.363 (95% CI: 0.260--0.508, *p* \<0.001) in a random effect model analysis (Additional file [1](#MOESM1){ref-type="media"}: Appendix 12). The funnel plot showed symmetry (Additional file [1](#MOESM1){ref-type="media"}: Appendix 13). However, the Egger's test revealed that intercept was 3.06 (95% CI: 0.295--5.831, t-value: 2.43, df: 11, *p* = 0.03 (2-tailed)). The rank correlation test showed a Kendall's tau of 0.28 with a continuity correction (*p* = 0.20). The trim and fill method indicated that no study was trimmed. After excluding an outlier (study by Kasahara A et al. \[[@CR17]\]) located on the left upper quadrant area in funnel plot, the OR was 0.398 (95% CI: 0.314--0.504, *p* \<0.001). Overall, the impact of bias was minimal.

A cumulative meta-analysis of enrolled studies based on publication year showed no specific time trend (Additional file [1](#MOESM1){ref-type="media"}: Appendix 14). A cumulative meta-analysis based on effect size showed no small study bias (Additional file [1](#MOESM1){ref-type="media"}: Appendix 15). One study removed meta-analysis revealed a stable feature (Additional file [1](#MOESM1){ref-type="media"}: Appendix 16). Overall, the sensitivity meta-analyses showed robust results.

A meta-ANOVA indicated that follow-up duration (*p* = 0.036) and methodological quality (*p* = 0.029) were suspicious for the reason of heterogeneity (Additional file [1](#MOESM1){ref-type="media"}: Appendix 17). A meta-regression indicated that follow-up duration (*p* = 0.036) and Newcastle-Ottawa scale score of 8 (*p* = 0.029) explained the heterogeneity (Additional file [2](#MOESM2){ref-type="media"}: Table S3). After excluding 2 studies (short-term follow-up duration), no covariates explained heterogeneity in meta-regression tests. After excluding 7 studies (Newcastle-Ottawa scale 8), no covariates explained heterogeneity in meta-regression tests. Therefore, follow-up duration and methodological quality were the reasons of heterogeneity in this analysis.

Efficacy of SVR on the development of HCC in patients with chronic hepatitis C {#Sec15}
------------------------------------------------------------------------------

The overall efficacy of SVR on the development of HCC exhibited an OR of 0.203 (95% CI: 0.164--0.251, *p* \<0.001) in a random effect model analysis (Fig. [4](#Fig4){ref-type="fig"}). The funnel plot showed symmetry (Additional file [1](#MOESM1){ref-type="media"}: Appendix 18). The Egger's test showed that intercept was 0.56 (95% CI: −0.099--1.217, t-value: 1.73, df: 33, *p* = 0.09 (2-tailed)). The rank correlation test showed a Kendall's tau of −0.17 with a continuity correction (*p* = 0.16). The trim and fill method indicated that no study was trimmed. Overall, there was no evidence of publication bias.Fig. 4Efficacy of SVR on the development of HCC in patients with CHC. The size of each square is proportional to the study's weight. Diamond is the summary estimate from the pooled studies (random effect model). SVR, sustained virologic response; HCC, hepatocellular carcinoma; CHC, chronic hepatitis C

A cumulative meta-analysis of enrolled studies based on publication year showed no specific time trend (Additional file [1](#MOESM1){ref-type="media"}: Appendix 19). A cumulative meta-analysis based on effect size showed no small study bias (Additional file [1](#MOESM1){ref-type="media"}: Appendix 20). One study removed meta-analysis showed a stable feature (Additional file [1](#MOESM1){ref-type="media"}: Appendix 21). Overall, the sensitivity meta-analyses revealed robust results.

Meta-ANOVA or meta-regression identified no specific modifier for the reason of heterogeneity (Additional file [1](#MOESM1){ref-type="media"}: Appendix 22) (Additional file [2](#MOESM2){ref-type="media"}: Table S4). Overall, no covariates explained heterogeneity.

Efficacy of SVR on all-cause mortality in patients with chronic hepatitis C {#Sec16}
---------------------------------------------------------------------------

The overall efficacy of SVR on all-cause mortality revealed an OR of 0.255 (95% CI: 0.199--0.326, *p* \< 0.001) in a random effect model analysis (Fig. [5](#Fig5){ref-type="fig"}). The funnel plot showed asymmetry on the right lower quadrant area (Additional file [1](#MOESM1){ref-type="media"}: Appendix 23). The Egger's test showed that the intercept was −1.44 (95% CI: −1.921-- −0.949, t-value: 6.16, df: 20, *p* \<0.001 (2-tailed)). The rank correlation test showed a Kendall's tau of −0.23 with a continuity correction (*p* = 0.14). The trim and fill method indicated 11 studies were trimmed. Overall, there was evidence of publication bias.Fig. 5Efficacy of SVR on all-cause mortality in patients with CHC. The size of each square is proportional to the study's weight. Diamond is the summary estimate from the pooled studies (random effect model). SVR, sustained virologic response; CHC, chronic hepatitis C

A cumulative meta-analysis of enrolled studies based on publication year showed no specific time trend (Additional file [1](#MOESM1){ref-type="media"}: Appendix 24). A cumulative meta-analysis based on effect size showed no small study bias (Additional file [1](#MOESM1){ref-type="media"}: Appendix 25). One study removed meta-analysis revealed a stable feature (Additional file [1](#MOESM1){ref-type="media"}: Appendix 26). Overall, the sensitivity meta-analyses showed robust results.

Meta-ANOVA indicated that methodological quality potentially explained heterogeneity (*p* = 0.030) (Additional file [1](#MOESM1){ref-type="media"}: Appendix 27). Meta-regression revealed a Newcastle-Ottawa scale score of 8 for the reason of heterogeneity (Additional file [2](#MOESM2){ref-type="media"}: Table S5). After excluding 16 studies (Newcastle-Ottawa scale 8), no covariates explained heterogeneity in meta-regression tests. Therefore, methodological quality was the reasons of heterogeneity in this analysis.

Efficacy of SVR on liver-specific mortality in chronic hepatitis C patients {#Sec17}
---------------------------------------------------------------------------

The overall efficacy of SVR on liver-specific mortality exhibited an OR of 0.126 (95% CI: 0.094--0.169, *p* \< 0.001) in a random effect model analysis (Additional file [1](#MOESM1){ref-type="media"}: Appendix 28). The funnel plot showed asymmetry on the right lower quadrant area (Additional file [1](#MOESM1){ref-type="media"}: Appendix 29). The Egger's test indicated that intercept was −0.77 (95% CI: −1.473 -- −0.057, t-value: 2.25, df: 21, *p* = 0.036 (2-tailed)). The rank correlation test revealed a Kendall's tau of −0.19 with a continuity correction (*p* = 0.20). The trim and fill method showed 6 studies were trimmed. Overall, there was evidence of publication bias.

A cumulative meta-analysis of enrolled studies based on publication year showed no specific time trend (Additional file [1](#MOESM1){ref-type="media"}: Appendix 30). A cumulative meta-analysis based on effect size showed no small study bias (Additional file [1](#MOESM1){ref-type="media"}: Appendix 31). One study removed meta-analysis revealed a stable feature (Additional file [1](#MOESM1){ref-type="media"}: Appendix 32). Overall, the sensitivity meta-analyses showed robust results.

Meta-ANOVA or meta-regression revealed no specific modifier for the reason of heterogeneity (Additional file [1](#MOESM1){ref-type="media"}: Appendix 33) (Additional file [2](#MOESM2){ref-type="media"}: Table S6). Overall, no covariates explained heterogeneity.

The results of meta-regression analyses for each topic are summarized in Table [7](#Tab7){ref-type="table"}.Table 7Results of meta-regression analysesModifierCoefficientStandard error*P* valueNOS (topic 1)NOS 8: 1.203\
NOS 7: 0.5010.565\
0.5610.033\
0.372\
Q: 7.24, df: 2, *P* = 0.027Follow-up duration (topic 3)1.1400.5420.036NOS (topic 3)NOS 8: −0.6590.3020.029NOS (topic 5)NOS 8: −0.540\
NOS 7: −0.5440.209\
0.3220.010\
0.091\
Q: 7.03, df: 2, *P* = 0.030*NOS* Newcastle-Ottawa scale

Discussion {#Sec18}
==========

This meta-analyses confirmed the long-term efficacy of antiviral treatment in terms of prevention of HCC and reduction in all-cause and liver-specific mortality in patients with chronic HCV infection. This long-term efficacy was also intensified when SVR was achieved. Clinical outcomes regarding the efficacy of antiviral therapy in CHC patients have been continuously investigated by previous studies with a small number of patients or short-term follow-up duration. The reasons for performing this meta-analysis were a persistent risk of HCC even after attainment of SVR and a lack of sufficient data regarding long-term efficacy \[[@CR18]\]. Persistent low-level of viremia and dysplastic hepatocyte regeneration are representative grounds for persistent risk of HCC after antiviral treatment \[[@CR19], [@CR20]\]. Interestingly, a recent meta-analysis revealed that IFN nonresponders exhibited a decreased risk of HCC recurrence after curative treatment of HCC, compared with no treatment patients, thus indicating that reduced necroinflammation and an inhibition of hepatic fibrosis progression prevent the development of HCC \[[@CR21]\]. This results is consistent with that of our study and emphasized the importance of screening strategy of chronic hepatitis C.

Early antiviral treatment before progression to advanced fibrosis or cirrhosis is associated with an increasing probability of achieving SVR \[[@CR22]\]. However, an indolent course of chronic hepatitis C makes it difficult for early diagnosis and treatment. Authors have revealed that favorable antiviral efficacy persists in all patients with chronic hepatitis C, regardless of histology. This result was also confirmed by a previous study indicating favorable antiviral efficacy even in patients with LC \[[@CR18]\]. Considering the advanced fibrosis or cirrhosis is the sequelae of long-standing inflammation of liver, our study confirmed antiviral treatment is still valid in the late course of chronic hepatitis C. Although histology was not a significant modifier in our meta-analysis, all of the included studies have substantially heterogeneous populations regarding the degree of fibrosis or cirrhosis of the liver. This finding was commonly detected in a previous meta-analysis \[[@CR18]\]. However, considering the expanding treatment indication, including decompensated LC by the advent of direct-acting antiviral agents, histology is not expected to affect the long-term efficacy of antiviral treatment in the near future.

Despite the favorable efficacy of antiviral treatment, 2 modifiers associated with heterogeneity were identified in the meta-ANOVA and meta-regression analyses. Studies with Newcastle-Ottawa scale of 8 were modifier in the analysis of association between antiviral treatment and the development of HCC (Additional file [2](#MOESM2){ref-type="media"}: Table S1), in the analysis of association between antiviral treatment and the liver-specific mortality (Additional file [2](#MOESM2){ref-type="media"}: Table S3), and in the analysis of association between SVR and all-cause mortality (Additional file [2](#MOESM2){ref-type="media"}: Table S5). Studies with a short-term follow-up duration were also modifier in the analysis of association between antiviral treatment and liver-specific mortality (Additional file [2](#MOESM2){ref-type="media"}: Table S3). Although these modifiers were confirmed as not significantly affecting the results of main analyses, this finding indicated the need for more number of high-quality and long-term follow-up studies on this topic.

Publication bias was detected in 2 topics (topic 5 and 6). Sensitivity analyses including cumulative and one study removed meta-analyses were rigorously performed to find the small study effect associated with publication bias, and these analyses showed no small study effect. Overall, the impact of publication bias was minimal.

This meta-analysis included the largest number of articles identified by a comprehensive literature search, and potential confounding modifiers were searched within each study whenever possible. Sensitivity analyses and meta-regression tests were performed to demonstrate robustness or identify the reason of heterogeneity. Despite the strengths, several limitations were detected during the systematic review. First, pretreatment predictive factors associated with the treatment response were not controlled or evaluated in these analyses, including pretreatment viral load, genotype, IL-28β polymorphism, and HBV or HIV coinfection. Direct-acting antiviral agents are expected to overcome these factors. Therefore, results of studies including these agents are expected in the near future. Second, the baseline characteristics of each enrolled study were not comparable between the treatment vs. no treatment groups, or the SVR vs. no SVR groups in some studies. This phenomenon was reflected in the evaluation of methodological quality and was confirmed to be a significant modifier associated with heterogeneity. Notably, difference by race or country including life style (obesity, consumption of alcohol or aflatoxin-contaminated foods, and chemical carcinogens exposure) was not appropriately investigated in our study. Considering the HCC is a heterogenous malignancy resulting from diverse causes of liver injury, different mechanisms or molecular pathways on the basis of country could be a cause of different treatment response. However, due to the heterogenous baseline characteristics including genotype and lacking of enough data about risk factors of HCC, the subgroup analyses by country could not present meaningful data. The limitations described above could be a cause of potential heterogeneity and bias. Therefore, studies controlling for various risk factors are needed to confirm these findings.

Conclusion {#Sec19}
==========

In conclusion, antiviral treatment for chronic hepatitis C showed improved outcome in the development of HCC and mortality, especially when SVR is achieved, although studies controlling for various risk factors of HCC and mortality are still lacking.

Additional files
================

 {#Sec20}

Additional file 1:Contains 33 figures including assessment of methodological quality, funnel plots for publication bias, sensitivity analyses, and Meta-ANOVA. (DOC 24248 kb) Additional file 2:Contains 6 tables including detailed meta-regression data of 6 study topics of this study. (DOC 79 kb)
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